Alternate dosing of cetuximab for patients with metastatic colorectal cancer

摘要: BACKGROUND: Many chemotherapeutic regimens used to treat colorectal cancer (CRC), including 5-fluorouracil plus leucovorin in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX), are administered on an every-other-week (q2w) dosing schedule. Chemotherapy a monoclonal antibody (mAb) directed toward the epidermal growth factor receptor (EGFR) has emerged as effective treatment option. There currently 2 anti-EGFR mAbs approved by United States Food and Drug Administration: cetuximab panitumumab. Mutations of KRAS, downstream protein EGFR pathway, predict resistance mAbs. Thus, panitumumab indicated for patients without KRAS mutation (KRAS wild-type). Whereas is q2w schedule, weekly dose. However, only FOLFIRI frontline metastatic CRC, whereas third-line. Because concomitant therapies often q2w, results additional medical office visits. DESIGN: Several studies have assessed safety efficacy q2w. For this review, comprehensive literature search evaluating was conducted. Safety these trials retrospective analyses were summarized reviewed. RESULTS: In general, comparable those obtained regimen. CONCLUSION: These data suggest that whom presents substantial burden their quality life, viable option benefit:risk profile similar